Treats neurofibromatosis type 1 (NF1). Sold as Koselugo. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Selumetinib (sold as Koselugo), first approved Sep 10, 2025, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Koselugo | Part D | $23.3M | +4% | 148 |
| Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN)Neurofibromatosis Type 1 (NF1) · AstraZeneca | — | Recruiting | Oct 22, 2026 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Neurofibromatosis Type 2, Vestibular Schwannoma · Beijing Tiantan Hospital | Phase 2 | Not yet recruiting | Jul 20, 2026 |
| Selumetinib for NF2-Related SchwannomatosisNeurofibromatosis Type 2, NF2 · Beijing Tiantan Hospital | Phase 2 | Not yet recruiting | Jul 16, 2026 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaAdvanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma · National Cancer Institute (NCI) | Phase 1 / Phase 2 | Recruiting | Jun 2, 2026 |
| Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese ChildrenPlexiform Neurofibromas (PN) · West China Hospital | Phase 2 | Not yet recruiting | Jan 8, 2025 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTMalignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) · AeRang Kim | Phase 1 / Phase 2 | Recruiting | Dec 16, 2024 |
| Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate CapsuleNeurofibromatosis 1 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Oct 1, 2024 |
| The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate CapsuleNeurofibromatosis 1 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Oct 1, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 10, 2025 | KoselugoNDA 219943 · New dosage form | Astrazeneca | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA